A class-action lawsuit has been filed against Boston Scientific Corp. (NYSE: BSX) alleging securities fraud after the company’s stock price fell 17.6% in a single day. The suit, filed on behalf of investors who purchased shares between July 23, 2025, and February 3, 2026, claims the company made materially false statements about its business.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, a founding partner of Bronstein, Gewirtz & Grossman, LLC, one of the firms that filed a complaint.
The legal action follows a significant stock drop on February 4, 2026, when Boston Scientific shares fell $16.12 to close at $75.50. The decline came after the company released fourth-quarter 2025 results that included lower-than-expected sales in its electrophysiology division and issued guidance for fiscal 2026 that was well below analyst expectations.
Investors now have until May 4, 2026, to file a motion with the court to serve as lead plaintiff in the case. The lead plaintiff represents the interests of all class members in the litigation.
The core of the complaint alleges that Boston Scientific failed to disclose adverse trends affecting its U.S. electrophysiology (EP) business. Lawsuits claim the company's projections for the segment's growth were not sustainable due to increasing competition and other headwinds.
The filings state that management was aware the U.S. EP segment was nearing a growth inflection point sooner than the market anticipated, rendering its positive statements and upward guidance revisions misleading. The company attributed its disappointing results and guidance to a combination of slower-than-expected market growth and increased competition.
The decline on February 4 puts the stock at its lowest point since early 2026, testing key technical support levels. For investors, the lawsuit introduces a new layer of uncertainty around the company's growth narrative. The next major catalyst will be the court's proceedings after the May 4 lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
